Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
Werewolf Therapeutics, Inc. (HOWL)
Company Research
Source: GlobeNewswire
WATERTOWN, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced that three posters will be presented at the upcoming Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting, taking place November 5-9, 2025, in National Harbor, Maryland.Details for the poster presentations are as follows: Title: Sequential administration of WTX-124 and mWTX-330, IL-2 and IL-12 INDUKINE™ molecules, enhanced antitumor activity in mice bearing poorly immunogenic EMT6 tumors without systemic toxicityAbstract Number: 861Session Date and Time: Nov. 7, 2025; 12:15-1:45, 5:10-6:35 p.m.Location: Poster Hall (Exhibit Halls A and B1) Title: Development of conditional T cell engagers (INDUCER™ molecules) wit
Show less
Read more
Impact Snapshot
Event Time:
HOWL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HOWL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HOWL alerts
High impacting Werewolf Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
HOWL
News
- Werewolf Therapeutics (NASDAQ:HOWL) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.MarketBeat
- Werewolf Therapeutics (NASDAQ:HOWL) had its price target lowered by analysts at Bank of America Corporation from $8.00 to $7.00. They now have a "buy" rating on the stock.MarketBeat
- Werewolf Therapeutics (NASDAQ:HOWL) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..MarketBeat
- Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual MeetingGlobeNewswire
- Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswire
HOWL
Earnings
- 11/4/25 - Beat
HOWL
Analyst Actions
- 11/12/25 - Citigroup Inc.
HOWL
Sec Filings
- 12/4/25 - Form 4
- 12/4/25 - Form 4
- 12/4/25 - Form 4
- HOWL's page on the SEC website